ARTICLE | Clinical News
Isentress raltegravir: Phase III data
February 29, 2016 8:00 AM UTC
Top-line data from the 96-week, double-blind, international Phase III ONCEMRK trial in about 750 treatment-naive patients with HIV-1 infection trial showed that a once-daily formulation of 1,200 mg ra...